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Summary Between February 1986 and July 1988 a total of 21 children aged I to 16 years with malignant
germ cell tumours (MGCT), 18 with either metastatic disease or unresectable primary tumour, received the
JEB regimen - carboplatin dosage calculated from the EDTA glomerular filtration rate (approximately
600 mg m-2), etoposide 120 mg m-2 daily x 3, and bleomycin 15 mg m 2 weekly. Primary sites were: testis (6),
ovary (8), sacrococcyx (4), pineal gland (2) and vagina (1). AFP levels were elevated in 19, P-HCG in 8.
Complete marker response was achieved in 19 out of 19 evaluable patients and complete remission of
measurable tumour in 16 out of 19, 12 with chemotherapy alone and 4 with the addition of surgery. A
reduction in glomerular filtration rate greater than 10% occurred in 3 of 12 evaluable patients; in none greater
than 20%. Sequential audiography was normal in 11 out of 12 evaluated. The regimen was myelosuppressive
with WHO grade III or IV myelosuppression occurring in 12 patients.
Three patients have relapsed; one with a pineal germinoma who relapsed in the abdomen six months after
diagnosis, and two with sacrococcygeal teratomas and lung metastases. Two of these remain in second
complete remission after further treatment. There was one death from probable bleomycin pulmonary toxicity.
We conclude that this regimen is simple to administer and, apart from myelosuppression, it is well tolerated. It
appears to have comparable efficacy to cisplatin-based regimens but with much less nephrotoxicity and
ototoxicity and avoids the use of alkylating agents and anthracyclines.
Dramatic improvement in cure rates of adults with malignant
germ cell tumours using cisplatin-based regimens have been
mirrored in paediatric practice (Einhorn & Donohue, 1977;
Peckham et al., 1983; Williams et al., 1987; Pinkerton et al.,
1986; Mann et al., 1987). With short-duration chemotherapy,
non-mutilating surgery and avoidance of radiotherapy or
alkylating agents, the majority of children, including many
with metastatic MGCT, can be cured. With such a
favourable outcome emphasis is now placed on avoiding
immediate and delayed toxicity. The PVB (cisplatin, vinblas-
tine, bleomycin) or BEP (bleomycin, etoposide, cisplatin)
regimens, without alkylating agents, probably avoid sterility
and reduce second malignancy risks but are accompanied by
significant renal and auditory toxicity. Even with careful
hydration, mannitol and monitoring of glomerular filtration
rate (GFR) by 51Cr-EDTA clearance, the majority of children
will have a significant fall in GFR. Though hearing loss
affects only high frequencies in most cases, it is still of
clinical significance (Brock et al., 1988). Although long-term
studies are few (Brock et al., 1988; Koliouskas et al., 1985),
there is little evidence that either renal function or hearing
loss shows meaningful improvement with time.
Substitution for cisplatin by a less toxic analogue such as
carboplatin has been shown to be effective in ovarian cancer
(Calvert et al., 1982; Wiltshaw et al., 1985) and this drug has
clear activity in adult Phase II studies with MGCT (Horwich
et al., 1988). There is, however, little or no evidence that
significant non-cross resistance exists in cisplatin-resistant
tumours and its use in the JEB regimen is primarily to avoid
toxicity. In this regimen, carboplatin is given at a dose based
on renal function calculated from the Calvert formula
(Calvert et al., 1989). This is predicted to produce an area
under the drug concentration curve (AUC) which may lead
to significant but manageable myelosuppression but possibly
maximum therapeutic effect. Early studies in adults show
clearly that inferior results are achieved with carboplatin
unless the dose is pushed to myelosuppressive levels (Hor-
wich et al., 1989).
Etoposide and bleomycin are used as in the standard BEP
regimen (Peckham et al., 1983). There is some controversy
about the necessity of weekly rather than 3-weekly
bleomycin. In this study, if it was possible to monitor lung
function, children were given this drug weekly. Infants,
whose lung function could not be tested, received bleomycin
3-weekly after the first two cycles of chemotherapy.
Patients and methods
Twenty-one children aged 1 to 16 years (median 11 years)
received the JEB regimen. Nineteen were previously un-
treated and two had received single courses of PVB and BEP
chemotherapy respectively. Clinical details are shown in
Table I. Serum markers (a-fetoprotein and P-HCG) were
estimated in all patients by immunoassay. Staging investiga-
tions included PA and lateral chest X-ray, CT chest scan,
isotope bone scan and abdominal ultrasound or CT scan.
Lymphography was not performed.
Indications for chemotherapy were the presence of meta-
static disease in lung (6), lymph nodes (6), or peritoneum (1);
bulky, unresectable primary tumour (5), peritoneal spill at
surgery (3), or an intracranial primary (2). The testis was the
primary site in 6 patients, ovary in 8 and sacrococcygeal area
in 4. A one-year-old infant with a large vaginal tumour was
treated electively with chemotherapy alone to avoid
mutilating surgery. One boy with a pineal germinoma
received JEB after complete resection and before irradiation.
A second patient with a pineal tumour had undergone
surgery but developed rapidly progressive disease within a
month of this. a-FP was elevated in 19 patients, P-HCG in 8.
In no patient was both x-FP and P-HCG normal. The
chemotherapy is outlined in Figure 1. Bleomycin (15 mg m-2)
was given weekly as a slow intravenous infusion. Etoposide
(120 mgm2) was administered daily x 3 as a 1 to 3 hour
infusion and carboplatin infused over one hour. The formula
for calculating the dose of carboplatin was based on the
uncorrected "Cr-EDTA clearance. In four children the GFR
was not measured before treatment and doses based on
surface area were given (400-500 mg m2). In four the car-
boplatin dose was given according to surface area despite the
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GFR being known, and in three patients an AUC of less
than 5 mgml-' min'l was electively chosen by the physician.
Tumour response was reassessed after 2 and 4 courses and
CR documented using markers and imaging with X-ray or
CT scan. Patients were given a minimum of four courses of
JEB with additional cycles dependent on initial bulk of
disease and the time to CR. Usually, chemotherapy was
continued for 2 courses beyond CR.
Table I Clinical characteristics of patients
Age at
diagnosis Patholog/a &
Patient (years) serum markers Sites ofdisease
1 1 Yolksac
a-FP 4000
11 Mixed yolk sac &
mature
a-FP 3000
11 Germinoma
a-FP 43
15 Yolk sac
a-FP 38
2 Yolk sac
a-FP 8855
13 Dysgerminoma
,B-HCG 99
15 Immature &
choriocarcinoma
x-FP 115
P-HCG 438
13 Yolk sac
choriocarcinoma
x-FP 7000
P-HCG 113000
16 Yolk sac &
mature
x-FP 1340
11 Yolksac&
mature
a-FP 45
1 Yolk sac
a-FP 545
16 Yolk sac
a-FP 155
P-HCG 592
(birth) No Biopsy
a-FP 23820
9 Yolk sac
a-FP 2015
P-HCG 1455
21 No Biopsy
a-FP 103000
14 Immature
a-FP 7300
12 1 Dysgerminoma
P-HCG 490
16 Immature
a-FP 25
P-HCG 13
8 No Biopsy
a-FP 1500
(CSF 2400)
171 Yolk sac
a-FP 291000
2 Yolk sac
a-FP 66000
P-HCG 105
aDehner classification (Dehner, 1986).
Relapse in abdominal
nodes 3/12 after testis
primary resected
Ovary (resected with
rupture)
Pineal mass; complete
macroscopic resection
Testis, (resected)
Para-aortic nodes
Sacrococcyx
Lung
Ovary (resected with
rupture). Para-aortic
nodes.
Testis, (resected)
Lung and para-aortic
nodes
Ovary
Lung
Ovary (resected)
Masses R. ovary &
peritoneum
Testis, para-aortic
nodes
Vagina
Testis (resected)
Bilateral lung 2°
Lung 2° 13/12 after
removal of 'benign'
sacrococcygeal teratoma
Ovary resected with
rupture
Sacrococcyx
Lung 2°
Ovary
Ovary
Testis, (resected)
Para-aortic nodes
Pineal
Ovary
Sacrococcyx
Day: 1 2 3 9 12
JM8a (Carboplatin) 4+
Bleomycin + + +
15mgm2 I.V.
Etoposide + + +
120mgm-2 I.V.
aDose mg = ([EDTA uncorrected x 1.2] + 20) x AUC (6).
Figure 1 Outline of JEB chemotherapy. Each course was
repeated at 21-day intervals provided the neutrophil count
> 1.0 x 1091-' and platelets >100 x 1091-l.
Monitoring Toxicity
Estimates of plasma urea and creatinine have been shown to
be inaccurate indicators of renal impairment in children
receiving cisplatin (Womer et al., 1985). 5'Cr-EDTA GFR
was therefore estimated before treatment and repeated during
treatment in most patients. Formal audiometry was done
during and following treatment in patients old enough to
co-operate. The hearing was graded according to a scale
devised specifically to quantify cisplatin-related ototoxicity in
children (Brock et al., 1988). In patients who could co-
operate, spirometric respiratory function tests and CO
diffusion tests were performed at intervals during and follow-
ing treatment.
Results
Tumour response and outcome
The total number of courses given ranged from 4 to 6
(median 4). Marker CR was achieved in all patients after
between two and four courses of chemotherapy. The
estimated serum a-FP tt ranged from 3 to 12 days (median 7
days) and of P-HCG from 3 to 15 days (median 4)
(Table III). One boy with a pineal germinoma (case No 3),
who had no measurable disease following initial surgery,
developed progressive abdominal disease with multiple
peritoneal seedlings, probably related to a ventriculo-
peritoneal shunt. Despite cranio-spinal irradiation and intro-
duction of an intensive cisplatin-containing regimen he failed
to respond. Patient 5 with a sacrococcygeal primary and lung
metastases, achieved rapid CR but tumour recurred at the
primary site 4 months after completion of treatment. Coccyx-
ectomy had not initially been performed electively because of
radiological CR at primary and metastatic sites. Patient 16
developed recurrent lung metastases 6 months after having
achieved CR.
With chemotherapy alone complete remission of disease on
X-ray or CT scan occurred in 12 of 18 evaluable patients;
residual primary disease was completely resected in 4 cases; 2
showed active tumour and 2 mature teratoma (Table IV).
'Second look' surgery was performed in 6 patients with no
imageable disease and confirmed clinical CR in each.
Minor residual abnormalities were seen on CT scan in
three patients but secondary surgery was not performed.
These abnormalities were in the abdomen in two cases and in
the lung in a third child. All abnormal CT images subse-
quently resolved and the patients remain free from disease.
One patient (number 10), developed progressive peritoneal
disease on CT scan during chemotherapy despite normaliza-
tion of a-FP levels. At laparotomy, the tumour was resected
and shown to consist entirely of differentiated teratoma. No
further treatment was given and she remains free from
disease 15 months from diagnosis.
Hearing was not evaluated in 7 patients because of their
young age. In one of 12 patients, adequately evaluated, there
was evidence of high tone hearing loss during treatment
(20 dB loss at 4 KHz), but this returned to normal 3 months
later. 5"Cr-EDTA clearance declined > 10% from the
original value in 3 of 12 patients adequately studied; 12, 15
and 20% respectively. (See Table II).
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Table II Number of JEB courses, toxicity and estimated AUC of carboplatin
5'Cr EDTA clearance
(mlmin' 1.73m -2)
(JEB course)
1 2 3 4 5 6
112 . 90 117 109 .
103 114 . 113 . 116
99 . 106 147 .
132
Haematological
toxicity
(WHO grade)
Gd 4 neut & tcp
Gd 3 neut; Gd 2 tcp
None
169 . Not documented
135 107 163
107 124 . 129
140 140 140 .
194 219 .
115 . 140 118 .
148 130 125 .
121 124 97 . 97
Gd 4 tcp
Gd 1 tcp
Gd 4 neut
Gd 1 tcp
Gd 3 neut
Not documented
Gd 3 neut
Gd 2 tcp
Gd 2 neut
Gd 1 tcp
Gd 4 neut & tcp
(Gd 4 sepsis)
142 129 125 . Gd I tcp
Gd I tcp
Gd 2 neut
112
63
138
170
112
129
Gd 4 tcp
Gd 3 neut
Gd 4 neut
(Gd 3 sepsis)
Not documented
Gd neut
Gd 4 tcp
(Gd 4 sepsis)
Gd 3 tcp
Gd 4 neut
Not documented
Not documented
Gd 4 tcp
neut = neutropenia: tcp = thrombocytopenia *( ) = dose given
As expected, haematological toxicity was comparatively
severe with over half the patients developing WHO grade III
or IV myelosuppression on one or more occasions. Platelet
transfusions were required in only two patients but three
required parenteral antibiotics for fever during neutropenic
periods. Chemotherapy was given on time in most patients
with a median interval between courses of 24 days (range
21-45).
Lung function tests were abnormal in two patients. One
girl (case No2) had a pre-existing restrictive defect which
persisted but did not worsen. One boy (case No 4) developed
radiological evidence of early bleomycin toxicity with co-
existing alterations in lung function tests. This was treated
with steroids and has resolved. Case No 14, a 16-month-old
girl, died with an acute pneumonitis 3 months after receiving
6 courses of JEB. No pathogen was identified and although
no autopsy was performed bleomycin appeared to be impli-
cated. She had received weekly bleomycin with each course
of JEB.
Discussion
This pilot study demonstrates both the efficacy and the
tolerability of substituting carboplatin for cisplatin, combined
with etoposide and bleomycin, in paediatric MGCT. In this
regimen, a carboplatin AUC of 5-6mgml1' min, which in
children with normal renal function is equivalent to approxi-
mately 600 mg m2, was recommended. This is somewhat
higher than the AUC recommended in adults (4-5) which is
predicted to result in moderately severe thrombocytopenia
(Calvert et al., 1989). As a single agent, at a dose of
400 mg m-2, carboplatin has produced high response rates in
untreated patients with localized seminomatous and non-
seminomatous germ cell tumours (NSGCT) (Horwich et al.,
1988). In one study using JEB in poor risk NSGCT in adults
only 40% achieved CR with chemotherapy and surgery
(Motzer et al., 1987). In that study, however, the dose of
carboplatin was only 350 mg m-2 which would yield an AUC
in the range of 2-3 mg ml min. With a higher dose of
No.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Number of
courses
given
4
5
4
4
(+BEP x 1)
5
6
4
4
5
4
4
6
6
6
5
4
5
4
4
2
4
(+BEP x 1)
Carboplatin
AUC
(mgmlt'min)
5
5
5
3
(400 mg m2)*
4.5
6
5
4
(600 mg m2)*
6
5
6
4.5
(400 mg m2)
4
(500 mg m2)
(400 mg m2)
(500 mg m2)
6.5
(500 mgm2)
4
(500 mg m2)
6
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Table III Clinical and tumour marker response and outcome
Time to marker
remission Time to clinical response
No. Half-life Evaluation ofresponse Outcome
1 CR 2 courses CR 4 courses NED
a-FP 6d No tumour at surgery
2 CR 2 courses Non evaluable NED
a-FP 5d
3 CR 2 courses Non evaluable Died
a-FP 12d Relapsed in
4 CR 4 courses Residual lung CT 'abnormalities'
PR + CR with surgery
'active tumour'
5 CR 3 courses CR 5 courses
a-FP 6d CT scan
6 CR 2 courses
a-FP 3d
7 NE*
8 NE*
CR 6 courses
CT scan
Lung CR 3 courses
Minimal CT abnormality in
abdomen. -) CR with surgery
'mature teratoma'
PR + CR
with surgery
'active tumour'
9 CR 3 courses NR + CR
a-FP 8d with surgery
'mature teratoma'
peritoneum
(6/12)
NED
Relapsed at
primary (4/12)
Resected -* CR2
NED
NED
NED
NED
Months
after
diagnosis
31
33
9
38
17
23
21
15
15
10 CR I course
a-FP 8d
11 CR 2 courses
a-FP 8d
12 CR 2 courses
a-FP 8d
13 CR 2 courses
a-FP 8d
14 CR 2 courses
HCG 4d
a-FP 7d
15 CR 5 courses
a-FP IOd
16 CR 2 courses
a-FP 5d
17 CR 3 courses
HCG 15d
18 CR I course
a-FP 6d
HCG 3d
19 CR 2 courses
a-FP 7d
20 CR 3 courses
a-FP NE
21 CR 4 courses
a-FE NE
'CR' 4 courses
Minimal CT abnormality
CR 4 courses
No tumour at surgery
'CR' 6 courses
Minimal CT abnormality
CR I course
CT scan
Non evaluable
CR 3 courses
CT scan
No tumour at surgery
CR 2 courses
CT scan
CR 3 courses
No tumour at surgery
CR 4 cycles
CT scan
CR 2 courses
CT scan
CR 2 courses
No tumour at surgery
CR 4 courses
No tumour at surgery
NED
NED
NED
Died.
Bleomcyin
lung
NED
Lung relapse
(6/12)
CR 2 after surg.
IF, Epi, VCR
NED
NED
NED
NED
NED
NED
NED = no evidence of disease. *inadequate data
13
10
19
5
15
17
41
11
9
12
20
11
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Table IV Response to chemotherapy in extra-cranial tumours
2 not evaluable
(Rupture at surgery) I 1 toxic death
CR I
1
(surgically proven in 6)
2 Relapsed -*2
.8 NED 9-31 mths
N = 19 JEB Minor CT Residue (2 abdomen, *1 lung) Remain NED 13, 19, *38 mths.
alone alone
CT Residue ->- Surgery 2 Active Disease NED 15, *38 CT Residue -* Surgery 2 Mature Tumour NED 15, 21
(* same patient)
NED = no evidence of disease
carboplatin and an estimated AUC of over 4 mg ml-' min- ,
39 out of 39 previously untreated metastatic NSGCT patients
achieved complete remission (Horwich et al., 1989). Because
of concern about compromising antitumour activity an AUC
of 5-6 was recommended in this study. Comparatively severe
myelosuppression was expected and accepted as a trade-off
against reduced renal and auditory toxicity. Formal ran-
domised studies comparing the regimen against PVB or BEP
are in progress in adults.
This study confirms that carboplatin is not associated with
the ototoxicity seen with the BEP regimen. There was a small
decline in GFR in a minority of children but in adults this
has been clearly shown to be transient (Hardy et al., 1990).
The role of bleomycin has not been addressed in this study
but major reservations have been expressed in the past about
weekly administration of this drug. Deaths from respiratory
failure have been reported in children receiving PVB (Mann
et al., 1987) and although other contributory factors may
have been involved, there is some reason for concern. A link
between cisplatin nephrotoxicity and bleomycin toxicity has
been suggested (Dalgleish et al., 1984). It is of note that one
patient in this series developed clear evidence of lung toxicity
although renal function remained normal after carboplatin.
A small non-randomised study in adults has suggested that a
reduced dose of bleomycin adversely affects the efficacy of
BEP, but this was only in patients where the etoposide dose
was also suboptimal (Brada et al., 1987). By contrast, with
full dose etoposide and cisplatin, the results were impressive
despite the reduction to 3-weekly bleomycin. Current studies
of BEP against EP in small bulk disease show little difference
(Levi et al., 1986; Stoter et al., 1987) but the question has not
been settled in high-risk patients. Limiting weekly bleomycin
to the first two cycles in patients who cannot have lung
function tests done is an option, or alternatively, only
monthly treatment could be given in all patients. At present,
there is a reluctance to omit the drug altogether in children,
but once the results of randomised studies in adults are
available this may be indicated. With the JEB regimen the
response rate is comparable to that in children receiving
cisplatin based regimens, with or without the addition of
alkylating agents (Pinkerton et al., 1986, Flamant et al.,
1984). With extra-cranial primaries a CR rate of 65% with
chemotherapy alone, and 84% with chemotherapy plus
surgery was achieved. All three patients not achieving CR
have had minimal CT abnormalities which have remained
unchanged, or resolved.
The role of surgery in gonadal disease is comparatively
clear and is a useful way to confirm CR after chemotherapy
or to resect any residual active disease. In the case of sac-
rococcygeal disease the necessity of coccyxectomy after
radiological CR has been questioned. This procedure is how-
ever justified as an elective measure because of the difficulty
in being sure that there is no residual tumour in this complex
bony structure. The operation should be safe and without
sequelae. In one child in the present series (No 5) disease
recurred locally in the coccyx despite apparent CR.
Radiotherapy has little role in paediatric MGCT except in
the event of refractory or relapsed disease. It continues to be
used in pineal tumours because of reservations about the
reliability of drug access to the CNS. It is becoming clear
that this concern may be unfounded in some cases (Rustin et
al., 1989). There are, however, no reports yet of large series
where radiotherapy was not given electively. It is likely that
information will be gained from small infants in whom
irradiation is omitted owing to concern about late sequelae.
Although there were no patients with very bulky media-
stinal primaries or bone marrow or bone metastases, this was
a comparatively high risk group and included six children
with lung metastases and six with nodal disease. The risk
categories devised for adult MGCT cannot readily be applied
to paediatric patients. The absolute peak serum x-FP or
P-HCG are not of the same significance as in adults provided
levels decline within a relatively short half-life. 'Bulk disease'
is difficult to define in the small child because the absolute
tumour volume may be of more importance than volume in
relation to the child's size. In adults, extragonadal tumours,
mediastinal tumours in particular, continue to pose a
therapeutic problem (Logothetis et al., 1985). This may be a
consequence of bulk disease or difficulty achieving complete
resection of residual disease. It is of note that prognosis
appears better with pure yolk sac histology in this subgroup.
It is likely that JEB will not be sufficient for some patients
and alternative strategies such as high-dose platinum and
etoposide or high-dose intensity regimens such as the BEP/
BOP or POMB/ACE may be necessary (Horwich et al., 1989;
Newlands et al., 1983). Evaluation of the JEB regimen in
unselected MGCT patients on a multicentre basis is currently
underway by the United Kingdom Children Cancer Study
Group. This study may help to define if there is a high risk
group of patients in whom more toxic chemotherapy is
justifiable.
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